Ultragenyx Pharmaceutical Currently Down Eight Consecutive Days, on Pace for Longest Losing Streak Since December 2024

Dow Jones07-18

Ultragenyx Pharmaceutical, Inc. $(RARE)$ is currently at $29.15, down $1.07 or 3.54%

 

--Would be lowest close since June 24, 2026, when it closed at $29.11

--On pace for largest percent decrease since July 16, 2026, when it fell 4.7%

--Currently down eight consecutive days; down 18.73% over this period

--Longest losing streak since Dec. 18, 2024, when it fell for eight straight trading days

--Worst eight day stretch since the eight days ending Jan. 8, 2026, when it fell 32.11%

--Down 13.81% this week; worst weekly performance since the week ending Feb. 13, 2026, when it fell 16.92%

--Down 12.7% month-to-date

--Up 26.74% year-to-date

--Down 83.57% from its all-time closing high of $177.39 on Dec. 23, 2020

--Up 10.79% from 52 weeks ago (July 18, 2025), when it closed at $26.31

--Down 20.22% from its 52-week closing high of $36.54 on Dec. 4, 2025

--Up 57.57% from its 52-week closing low of $18.50 on March 24, 2026

--Traded as low as $28.90; lowest intraday level since June 23, 2026, when it hit $28.50

--Down 4.37% at today's intraday low

 

All data as of 3:33:11 PM ET

 

Source: Dow Jones Market Data, FactSet

 

(END) Dow Jones Newswires

July 17, 2026 15:35 ET (19:35 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment